MedTrace Logo

A Study of Apabetalone in Subjects With Long -COVID

NCT06590324 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-04-18

No results posted yet for this study

Summary

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

Conditions

  • Post-Acute COVID-19 Syndrome

Interventions

DRUG

Apabetalone

100-mg capsule, twice daily oral administration with meals

Sponsors & Collaborators

  • Resverlogix Corp

    lead INDUSTRY

Principal Investigators

  • Michael Sweeney, MD · Resverlogix Corp

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2025-12-30
Completion
2026-03-30

Countries

  • Jordan
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06590324 on ClinicalTrials.gov